6,939 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,939 shares of the biopharmaceutical company’s stock, valued at approximately $292,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Alkeon Capital Management LLC grew its position in Ultragenyx Pharmaceutical by 34.3% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after purchasing an additional 769,884 shares during the period. Two Sigma Advisers LP grew its holdings in shares of Ultragenyx Pharmaceutical by 123.4% during the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock valued at $54,872,000 after buying an additional 545,600 shares during the last quarter. Fisher Asset Management LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $11,156,000. Prudential Financial Inc. increased its position in shares of Ultragenyx Pharmaceutical by 659.5% during the fourth quarter. Prudential Financial Inc. now owns 272,940 shares of the biopharmaceutical company’s stock worth $11,483,000 after acquiring an additional 237,003 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. raised its holdings in shares of Ultragenyx Pharmaceutical by 49.1% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 633,715 shares of the biopharmaceutical company’s stock worth $35,203,000 after acquiring an additional 208,715 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $38.89 on Friday. The business’s fifty day moving average price is $41.68 and its 200-day moving average price is $47.03. Ultragenyx Pharmaceutical Inc. has a one year low of $36.71 and a one year high of $60.37. The stock has a market capitalization of $3.60 billion, a PE ratio of -6.13 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. As a group, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on RARE shares. Wells Fargo & Company boosted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. Piper Sandler lowered their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. Canaccord Genuity Group lifted their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. boosted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.79.

Insider Buying and Selling

In other news, CFO Howard Horn sold 1,785 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the sale, the chief financial officer now directly owns 106,169 shares in the company, valued at $4,289,227.60. This represents a 1.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider John Richard Pinion sold 14,439 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $607,881.90. Following the completion of the sale, the insider now directly owns 107,766 shares in the company, valued at approximately $4,536,948.60. The trade was a 11.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,370 shares of company stock valued at $5,751,499. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.